Clinical trials: Acromegaly
Acromegaly
Description of Sign-and-symptom Associations at Acromegaly Diagnosis.
The purpose of this study is to describe most characteristic association of signs and symptoms present at the time of acromegaly diagnosis.
- Trial name
- ACRO-POLIS (NCT02012127)
- Where
- 25 sites in France
- Volunteers
- 648 people
- Sponsor
- Ipsen
Acromegaly
Treatment Patterns and Treatment Outcomes for Acromegaly
This is a human, prospective and retrospective, single-center study of patients who have undergone treatment for acromegaly in New York City since 1981.
- Trial name
- NCT03043586
- Where
- United States
- Volunteers
- 520 people
- Sponsor
- Columbia University
Acromegaly
Pasireotide LAR and Pegvisomant Study in Acromegaly
The objective of this study is to assess the efficacy of Pasireotide Long Acting Release (LAR) alone and in combination with weekly Pegvisomant (PEGV) in acromegaIy patients previously controlled with combination treatment of…
- Trial name
- PAPE (NCT02668172)
- Testing
- Pasireotide LAR 60 mg, Pegvisomant
- Where
- Netherlands
- Volunteers
- 60 people
- Sponsor
- Erasmus Medical Center
Acromegaly
Cardiac (CMRI) Assessment of Acromegaly
In this study, the investigators will evaluate the cardiac structure and function, focusing on the myocardial water content and interstitial fibrosis, in patients with active acromegaly in comparison with 1) healthy volunteers…
- Trial name
- ACROCOEUR (NCT02948322)
- Testing
- CMRI, Gadolinium, OGTT
- Where
- France
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Endocrine Disorders, Adiposity
Neuroendocrine Mechanisms in Adiposity: An Integrated Approach to the Characterization of Potential Pharmacological Novel Targets Based on Experimental and Clinical Models
The goal of this observational study is to evaluate, retrospectively and prospectively, the effect of different hormonal and neuropeptide dysfunctions on the body composition of patients suffering from hypothalamic-pituitary…
- Conditions
- Endocrine Disorders, Adiposity, Pituitary Adenoma, Cushing Syndrome
- Trial name
- NCT06326853
- Volunteers
- 200 people
- Sponsor
- IRCCS San Raffaele
Acromegaly Due to Pituitary Adenoma, Acromegaly
Effects of Pasireotide Lar Therapy on Bone Metabolism
Acromegaly, a chronic condition characterized by growth hormone (GH) and, in turn, insulin-like growth factor-1 (IGF-I) excess, is burdened by a series of systemic and metabolic comorbidities that strongly impair quality of life…
- Trial name
- Pasi-Bone (NCT07179926)
- Testing
- morphometric spine radiography
- Where
- Italy
- Volunteers
- 120 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Acromegaly
Study in Polish Acromegalic Patients Treated With Somatuline Autogel
The purpose of this study is to evaluate over the 24 month prospective follow up - in everyday clinical practice - resource utilization and effectiveness of the treatment of acromegalic patients in Poland with Somatuline Autogel…
- Trial name
- NCT01333384
- Where
- Poland
- Volunteers
- 150 people
- Sponsor
- Ipsen
Acromegaly
Growth Hormone, IGF-1 and Medical Treatment in Acromegaly: Are There Effects on Gut Hormone Physiology and Postprandial Substrate Metabolism?
Acromegaly is a rare hormonal disorder leading to increased morbidity and mortality. In the vast majority of cases, a pituitary somatotroph cell adenoma causes excess growth hormone (GH) secretion, leading to hepatic…
- Trial name
- NCT02152124
- Where
- Belgium
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University Hospital, Ghent
Acromegaly, Osteoporosis Risk
Bone MicroArchitecture in Acromegaly
The investigators will conduct a cross-sectional study of bone density, bone microarchitecture, vertebral fractures and trabecular bone score in 25 patients with acromegaly treated with Pegvisomant, the growth hormone (GH)…
- Trial name
- NCT03225040
- Testing
- Pegvisomant
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Columbia University
Acromegaly
Hypoproteic Diet in Acromegaly
Since protein and AAs are master regulator of GH and IGF-I secretion, we hypothesized that a low protein diet could reduce GH and IGF-I levels in acromegalic patients in addition to conventional therapy.
- Trial name
- IpoProAcro (NCT05298891)
- Testing
- Usual clinical practice + hypoproteic diet
- Where
- Italy
- Volunteers
- 12 people
- Sponsor
- Azienda Ospedaliero Universitaria Maggiore della Carita
Acromegaly, Neuroendocrine Tumors
Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)
This is a Phase II, open-label multicentre, randomised study to assess the PK, PD, efficacy, and safety of two dosing regimens of CAM2029 in adult patients with acromegaly or a functional, well-differentiated NET, with carcinoid…
- Trial name
- NCT02299089
- Testing
- octreotide FluidCrystal® injection depot
- Where
- 10 sites in France, Germany and 2 more
- Volunteers
- 12 people
- Sponsor
- Camurus AB
Pituitary Disease
Safety and Efficacy of Pegvisomant in Children With Growth Hormone Excess
Background: For children with gigantism, too much growth hormone (GH) in the body causes abnormal growth and many other problems. Current treatments often don t work; no medical treatment is approved by FDA.
- Trial name
- NCT03882034
- Testing
- Pegvisomant
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Cushing's Disease, Acromegaly
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
The purpose of this study is to allow continued use of pasireotide in patients who are on pasireotide treatment in a Novartis-sponsored study and are benefiting from the treatment as judged by the investigator.
- Conditions
- Cushing's Disease, Acromegaly, Neuroendocrine Tumors, Pituitary Tumors
- Trial name
- NCT01794793
- Testing
- Pasireotide, Cabergoline, Pasireotide LAR
- Where
- 94 sites in United States, Argentina and 26 more
- Volunteers
- 337 people
- Sponsor
- RECORDATI GROUP
Acromegaly
SAGIT for Classification of Patients With Acromegaly in Clinical Practice
The purpose of this pilot study is to test SAGIT (Signs and symptoms - Associated comorbidities - GH concentration level - IGF-1 - Tumour).
- Trial name
- SAGIT Pilot (NCT02231593)
- Testing
- SAGIT
- Where
- 21 sites in United States, Brazil and 5 more
- Volunteers
- 71 people
- Sponsor
- Ipsen
Acromegaly
Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly
The purpose is to compare the efficacy and safety of lanreotide autogel® 60mg, 90mg or 120mg with lanreotide 40mg PR in subjects with active acromegaly.
- Trial name
- LANTERN (NCT02493517)
- Testing
- Lanreotide Autogel®, Lanreotide Acetate
- Where
- 10 sites in China
- Volunteers
- 128 people
- Sponsor
- Ipsen
Acromegaly
Long-term Safety and Efficacy Study of Octreotide Implant in Patients With Acromegaly
This is a long term study to evaluate the safety, tolerability and efficacy of an Octreotide Implant in patients that were previously treated with an Octreotide implant.
- Trial name
- NCT01295060
- Testing
- Octreotide
- Where
- 6 sites in United States
- Volunteers
- 12 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Acromegaly, Insulin Resistance
Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic Patients
The purpose of this study is to investigate if co-treatment of acromegalic patients, who beforehand are considered well-controlled on SA monotherapy, with pegvisomant and SA will improve insulin sensitivity and glucose tolerance…
- Conditions
- Acromegaly, Insulin Resistance, Impaired Glucose Tolerance
- Trial name
- NCT00652379
- Testing
- Pegvisomant, Somatostatin analog (lanreotide or octreotide)
- Where
- Denmark
- Volunteers
- 18 people
- Sponsor
- University of Aarhus
Acromegaly, Growth Hormone Treatment
Acromegaly - Before and After Treatment
The aim of the study is to investigate sleep apnea, circulation and metabolism in acromegaly before and after surgery and/or medical treatment.
- Conditions
- Acromegaly, Growth Hormone Treatment, Sleep Apnea, Cardiovascular Diseases
- Trial name
- NCT03431727
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- University of Aarhus
Sleep Apnea Syndrome
Prevalence of Acromegaly in a Diagnostic Consultation for Sleep Apnea Syndrome
Prevalence of sleep apnea syndrome in patients with acromegaly is about 70%. It seems that comorbidities of arterial hypertension or type 2 diabetes are more severe in patients with acromegaly and sleep apnea syndrome.
- Trial name
- ACROSAS (NCT02789696)
- Testing
- Diagnosis of acromegaly
- Where
- France
- Volunteers
- 880 people
- Sponsor
- University Hospital, Grenoble
Acromegaly Due to Pituitary Adenoma, Cushing's Disease
PRESTO: A Phase III Randomised Controlled Trial of Dose-escalated Proton Beam Therapy Versus Standard of Care Radiotherapy for Functioning Pituitary Tumours
The goal of this clinical trial is to evaluate whether a higher dose of radiotherapy can lead to better outcomes for participants with functioning pituitary tumours.
- Conditions
- Acromegaly Due to Pituitary Adenoma, Cushing's Disease, Pituitary Adenoma
- Trial name
- PRESTO (NCT07813351)
- Testing
- Standard dose Intensity-Modulated Radiation Therapy (IMRT), Standard dose Proton Beam Therapy (PBT), Escalated dose Proton Beam Therapy (PBT)
- Volunteers
- 82 people
- Sponsor
- University College, London